These press releases are for business and financial media.
-
- 01 August 2000
- ASTRAZENECA HALF YEAR RESULTS NARRATIVE Profit before tax up 19 per cent; EPS up 18 per cent. Download PDF (38Kb)
-
- 31 July 2000
- ASTRAZENECA ANNOUNCES APPOINTMENT OF GLOBAL E-BUSINESS VICE PRESIDENT AstraZeneca today announced the appointment of Kathleen Sheehan to the position of Vice President, Global eBusiness, reporting to John Patterson, Executive Vice President of Product Strategy & Licensing.
-
- 31 July 2000
- ASTRAZENECA CONTINUES RAPID DEVELOPMENT OF NEW CHOLESTEROL LOWERING DRUG WITH £28.5M MANUFACTURING PLANT INVESTMENT AstraZeneca today kept up the rapid pace of development of ZD4522, a new statin for lowering cholesterol, by announcing a £28.5m investment to build a new bulk medicine manufacturing plant at its Avlon Works, Severnside, near Bristol.
-
- 28 July 2000
- ASTRAZENECA MERGES JAPANESE SUBSIDIARIES AstraZeneca and Sumitomo Chemical Company Limited, of Osaka, today announced an agreement to merge AstraZeneca K.K. and Zeneca Yakuhin K.K from October 1, (2000). The shareholding of the merged company, AstraZeneca K.K, will be owned 80 per cent by AstraZeneca and 20 per cent by Sumitomo Chemical Company.
-
- 26 July 2000
- EUROPEAN COMMISSION APPROVES SYNGENTA MERGER AstraZeneca and Novartis announced today that the European Commission (EC) has cleared the planned merger of the Zeneca Agrochemicals business with the Novartis Agribusiness to form Syngenta AG, the world's first global dedicated agribusiness company.
-
- 03 July 2000
- NOLVADEX RECEIVES NEW FDA APPROVAL FOR USE IN PATIENTS WITH DUCTAL CARCINOMA IN SITU (DCIS) AstraZeneca announced today that the U.S. Food and Drug Administration (FDA) has approved its breast cancer drug Nolvadex to reduce the risk of invasive breast cancer in women with ductal carcinoma in situ (DCIS) following breast surgery and radiation. Nolvadex is the first medication to be approved for DCIS, which accounts for nearly 20 per cent of all newly diagnosed breast cancer cases [1] .
-
- 29 June 2000
- ASTRAZENECA's NEW STATIN SHOWS POTENTIAL TO IMPROVE TREATMENT FOR THE WORLD's LEADING CAUSE OF DEATH The first phase II clinical trial data for ZD4522, AstraZeneca's new statin, were presented today at the XIIth International Symposium on Atherosclerosis in Stockholm, demonstrating its potential to be a highly effective and well tolerated alternative to currently available statins [1] .
-
- 27 June 2000
- ASTRAZENECA EXPANDS US PRESENCE WITH NEW $100M RESEARCH CENTRE AstraZeneca today announced the opening of its newest research centre, AstraZeneca R&D Boston. The $100 million research centre houses 130 scientists researching infectious diseases, cancer and high-throughput screening technologies that enable novel, scientific approaches to pharmaceutical research.
-
- 21 June 2000
- ASTRAZENECA FILES LAWSUIT AGAINST LEK PHARMACEUTICAL AND CHEMICAL COMPANY D.D. AstraZeneca today announced that it has filed a lawsuit in New York against LEK Pharmaceutical and Chemical Company d.d. (LEK) and its US subsidiary, LEK USA, Inc. for patent infringement.
-
- 05 June 2000
- ASTRAZENECA FILES U.S. NDA FOR ZOMIG FAST MELT FORMULATION AND HAS GAINED APPROVAL IN 13 EUROPEAN COUNTRIES AstraZeneca today announced it has filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for its fast melt formulation of Zomig for the acute treatment of migraine. The tablet melts within seconds on the tongue and provides migraineurs with a more convenient method of relieving their migraine.
-
- 31 May 2000
- ASTRAZENECA EXTENDS MANUFACTURING AGREEMENT WITH SUMITOMO PHARMACEUTICALS TO BOOST 'Merrem/MERONEM'WORLD-WIDE SUPPLY AstraZeneca has extended an existing agreement with Sumitomo to significantly increase production for AstraZeneca's ultra-broad-spectrum antibiotic meropenem, known commercially as 'Merrem'and 'Meronem'. As a result of the agreement, the overall supply of 'Merrem/Meronem'is expected to double by 2003, with immediate supply in 2000 expected to increase by 40 per cent.
-
- 31 May 2000
- ASTRAZENECA PLC ANNOUNCES THE RESULTS OF THE POLLS TAKEN AT ITS ANNUAL GENERAL MEETING ON FRIDAY 26 MAY 2000 AstraZeneca PLC announces the results of the polls taken at its Annual General Meeting on Friday 26 May 2000 in respect of Items 8 and 9 on the Agenda, as follows:
-
- 26 May 2000
- PERCY BARNEVIK'S SPEECH AT THE ASTRAZENECA AGM, 26TH MAY Download PDF of speech (602k Acrobat .pdf)
-
- 26 May 2000
- TOM MCKILLOP'S SPEECH AT THE ASTRAZENECA AGM, 26TH MAY 2000 Download PDF of speech (602k Acrobat .pdf)
-
- 24 May 2000
- ASTRAZENECA's IRESSATM (ZD1839) DEMONSTRATES ENCOURAGING ANTI-TUMOUR ACTIVITY IN NON-SMALL CELL LUNG CANCER AstraZeneca today announced that final results from Phase I clinical trials of its novel anti-cancer compound known as Iressa™ or ZD1839, show, in a small number of patients, encouraging anti-tumour activity or disease stabilisation, particularly in non-small cell lung cancer. The data were presented at the American Society of Clinical Oncology (ASCO) annual meeting in New Orleans.
-
- 17 May 2000
- STOCK EXCHANGE ANNOUNCEMENT ASTRAZENECA - EU COMPETITION AUTHORITY AstraZeneca confirms that the European Commission earlier this year made enquiries in February 2000 relating to AstraZeneca's defence of its intellectual property and other rights relating to omeprazole.
-
- 16 May 2000
- ASTRAZENECA FILES LAWSUITS AGAINST EON LABS MANUFACTURING, INC. AND IMPAX LABORATORIES, INC. AstraZeneca filed lawsuits today in New York against Eon Labs Manufacturing, Inc. (Eon) and in Delaware against Impax Laboratories, Inc. (Impax) for patent infringement.
-
- 15 May 2000
- FDA APPROVES ASTRAZENECA's STERILE FACILITY TO MANUFACTURE AND DISTRIBUTE MERREM I.V. CREATES INCREASED U.S. SUPPLY OF BROAD SPECTRUM ANTIBIOTIC
-
- 15 May 2000
- FDA GRANTS ORPHAN DRUG STATUS TO ASTRAZENECA FOR MERREM® I.V. TO RESEARCH TREATMENT FOR CYSTIC FIBROSIS The U.S. Food and Drug Administration (FDA) announced today that it has granted AstraZeneca USA orphan drug status for its anti-infective medicine, Merrem® I.V. Currently, Merrem® I.V. is indicated in the USA for intra-abdominal infections in adults and children, and bacterial meningitis in children three months of age and older. Outside the USA, Merrem® is licensed for use in a wide range of infections.
-
- 25 April 2000
- ASTRAZENECA OBTAINS FIRST APPROVAL FOR SELOKEN® ZOK FOR THE TREATMENT OF HEART FAILURE AstraZeneca today announced that the beta blocker, Seloken® ZOK, has gained its first approval for the treatment of heart failure, an important extension to the existing range of cardiovascular indications for Seloken® ZOK which include angina, hypertension and post-myocardial infarction. The licence approval was granted in Denmark and the company expects to gain further approvals in other European countries and the US later this year.
-
- 13 April 2000
- ASTRAZENECA RECEIVES EUROPEAN APPROVAL OF ARIMIDEX® FOR FIRST-LINE TREATMENT OF POST-MENOPAUSAL WOMEN WITH ADVANCED BREAST CANCER AstraZeneca today announced it has received approval from the UK and five other European countries to extend the use of Arimidex® into first line treatment for post menopausal women with advanced breast cancer.
-
- 11 April 2000
- ASTRAZENECA FILES NDA FOR ZOMIG® (ZOLMITRIPTAN) - POTENTIALLY FIRST ORAL TRIPTAN IN JAPAN Japan, April 11, 2000: AstraZeneca today announced that it has submitted a new drug application for Zomig (zolmitriptan) for the acute treatment of migraine with or without aura. Potentially this could be the first oral triptan to be approved in Japan.
-
- 03 April 2000
- ASTRAZENECA ONCOLOGY PIPELINE FEATURED AT AMERICAN ASSOCIATION OF CANCER RESEARCH (AACR) 2000 MEETING Novel approaches to selectively targeting the processes that make cancer cells grow are being prominently featured at this week's American Association of Cancer Research meeting in San Francisco, USA. Three of these 'novel approach' compounds - ZD1839 ('Iressa'), ZD6474 and ZD6126 - all products of the innovative research and in-licensing programme at AstraZeneca, will be featured.
-
- 21 March 2000
- ASTRAZENECA TO APPEAL DECISION BY GERMAN PATENT COURT AstraZeneca today announced that the company will appeal a ruling handed down by the German Federal Patent Court. The Patent Court nullified the formulation patent for omeprazole in Germany. The patent covering the formulation, expiring in 2007, has been subject to nullity actions by the generic manufacturing companies Azupharma GmbH & Co and ratiopharm GmbH. Omeprazole is the active ingredient in Losec®.
-
- 21 March 2000
- EU REVIEW OF SYNGENTA TRANSACTION EXTENDED: COMPLETION IN SECOND HALF 2000 STILL ANTICIPATED AstraZeneca PLC today confirmed that the European Commission has initiated a Second Phase Investigation into the proposed spin off and merger of its agrochemicals business with Novartis' crop protection and seeds business.
-
- 14 March 2000
- FDA GRANTS ASTRAZENECA PRIORITY REVIEW FOR NOLVADEX® FOR TREATMENT OF DUCTAL CARCINOMA IN SITU (DCIS), A COMMON TYPE OF NON-INVASIVE BREAST CANCER The U.S. Food and Drug Administration (FDA) has granted a six-month priority review to AstraZeneca's breast cancer drug NOLVADEX® (tamoxifen citrate) for the adjuvant treatment of ductal carcinoma in situ (DCIS) in women following breast surgery and radiation. AstraZeneca filed a supplemental new drug application with the FDA for the DCIS indication in December 1999.
-
- 13 March 2000
- ASTRAZENECA's NEXIUM® RECEIVES FAST FIRST APPROVAL IN SWEDEN WITH WIDE RANGE OF INDICATIONS AstraZeneca today announced the initial approval of Nexium® (esomeprazole) with fast clearance given by the Swedish Medical Product Agency (MPA) for a broad range of indications, including two new treatment approaches.
-
- 10 March 2000
- ASTRAZENECA's OMEPRAZOLE SUBSTANCE PATENT UPHELD IN GERMANY AstraZeneca today welcomed a decision by the German Federal Patent Court to dismiss an attack on the substance patent for omeprazole. In Germany, AstraZeneca's substance patent for omeprazole expired in April 1999. As the patent still is the basis for the Supplementary Protection Certificate (SPC) in Germany, it has been subject to a nullity action by the company Merck-dura GmbH. Omeprazole is the active ingredient in Losec®.
-
- 08 March 2000
- LARGEST EVER BETA-BLOCKER STUDY SHOWS ASTRAZENECA's TOPROL-XL/SELOKEN ZOK IMPROVES CHF PATIENTS SURVIVAL Results of an international study published today in the Journal of the American Medical Association (JAMA) show that adding AstraZeneca's beta-blocker Toprol-XL/Seloken ZOK to standard treatment in patients with congestive heart failure improved survival, reduced hospitalisations and improved patients' well-being. The MERIT-HF study (Metoprolol CR (controlled release) Randomised Intervention Trial in Heart Failure) is the largest heart failure trial ever completed, involving nearly 4000 patients, to
-
- 06 March 2000
- ASTRAZENECA PLANS TO DIVEST UK PACKAGING SITE AT CORBY AstraZeneca plans to divest its UK packaging plant at Corby, Northamptonshire, as a going concern.
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 09:00 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
